Nasal Congestion News and Research

RSS

Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation

Hot chili peppers are known to make people "tear up," but a new study led by University of Cincinnati allergy researcher Jonathan Bernstein, MD, found that a nasal spray containing an ingredient derived from hot chili peppers (Capsicum annum) may help people "clear up" certain types of sinus inflammation.

26 Aug 2011

Study finds clear link between clinic accessibility and emergency room visits

David Jones, a graduate student in the University of Alberta's School of Public Health, along with Linda Carroll, professor in the School of Public Health, and Leonard Frank, executive director of the Leduc Beaumont Devon Primary Care Network, recently completed a study that examined whether or not there was a clear association between the number of visits to the emergency department and the availability of an after-hours care clinic in Leduc, Alberta.

11 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Extreme heat and rain lead to higher mold count in the Midwest

A record 7 inches of rain combined with the spate of 100-plus-degree days has spawned the highest mold count recorded for the year, just short of an air pollution warning.

27 Jul 2011

Public disclosure of Bachmann's migraine condition raises much-needed awareness

University of Vermont Professor of Neurology and migraine expert Robert Shapiro, M.D., Ph.D., says U.S. Representative and presidential candidate Michele Bachmann's public disclosure of her migraine condition has brought much-needed awareness to this disabling, often-stigmatized disorder, which afflicts millions of Americans.

21 Jul 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable system for severe headaches, today announced positive preliminary findings from a study evaluating the safety and efficacy of the company's investigational neurostimulation system for the treatment of cluster headache.

27 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

Positive results from Meda's Dymista Phase III trial in patients with SAR

Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.

22 Mar 2011

Survey: AR symptoms continue to impact patients' daily activities

Results from a recent pivotal allergic rhinitis satisfaction survey assessing patient and healthcare provider perspectives on AR reveal that symptoms like nasal congestion and post-nasal drip continue to impact patients' daily activities.

22 Mar 2011

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

22 Mar 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

Study reveals nasal congestion can be a sign of severe asthma

Nasal congestion can be a sign of severe asthma, which means that healthcare professionals should be extra vigilant when it comes to nasal complaints. Furthermore, more severe asthma appears to be more common than previously thought, reveals a study from the Sahlgrenska Academy's Krefting Research Centre.

21 Dec 2010

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).

7 Dec 2010

Bed rest may harm mother and baby in pregnancy complications

Bed rest may not be the best option for preventing preterm labor and may even cause harm to the mother and baby, according to an integrative literature review in a special issue on "Women's Health Across the Lifespan" in Biological Research for Nursing (published by SAGE).

30 Oct 2010

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

2 Sep 2010

Nasal Congestion News and Research

Nasal spray with hot chili pepper ingredient may help people clear up sinus inflammation

Study finds clear link between clinic accessibility and emergency room visits

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Extreme heat and rain lead to higher mold count in the Midwest

Public disclosure of Bachmann's migraine condition raises much-needed awareness

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

Positive preliminary findings from ATI's neurostimulation system study on cluster headache

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Positive results from Meda's Dymista Phase III trial in patients with SAR

Survey: AR symptoms continue to impact patients' daily activities

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Study reveals nasal congestion can be a sign of severe asthma

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

Bed rest may harm mother and baby in pregnancy complications

Inhibitex completes INX-189 Phase1a trial for HCV

Event guide: 4th Nasal Formulation & Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News